Metformin plus oral contraceptive may decrease plasma sCD40 ligand in women with PCOS patients

Kebapcilar, Levent; Kebapcilar, Ayse; Bilgir, Oktay; Taner, Cuneyt; Bozkaya, Giray; Yildiz, Yasar; SARI, İSMAİL

doi:10.3109/09513590.2010.491164

Metformin plus oral contraceptive may decrease plasma sCD40 ligand in women with PCOS patients

Kebapcilar L., Kebapcilar A. G., Bilgir O., Taner C. E., Bozkaya G., Yildiz Y., ...Daha Fazla

GYNECOLOGICAL ENDOCRINOLOGY, cilt.27, sa.2, ss.91-95, 2011 (SCI-Expanded, Scopus)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 27 Sayı: 2
Basım Tarihi: 2011
Doi Numarası: 10.3109/09513590.2010.491164
Dergi Adı: GYNECOLOGICAL ENDOCRINOLOGY
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Sayfa Sayıları: ss.91-95
Anahtar Kelimeler: sCD40L, metformin, ethinyl oestradiol plus cyproterone acetate, PCOS
Dokuz Eylül Üniversitesi Adresli: Evet

Özet

Methods. Total of 60 patients with PCOS was studied to evaluate and compare with a non-PCOS group consisting of 30 subjects. A low-dose oral contraceptive containing ethinyl oestradiol-cyproterone acetate (EE/CA) and metformin (M; 850 mg metformin twice a day) were given for three cycles. Plasma sCD40L was measured before and after the treatment of 3 months.